PhoreMost
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingServices
PhoreMost firmographics
Firmographics- Name
- PhoreMost
- Legal name
- PhoreMost Limited
- Website
- https://phoremost.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
PhoreMost industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
- akta.pro secondary industries
- Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
Keywords
Where PhoreMost is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
PhoreMost business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Collaboration Agreements: PhoreMost generates revenue through multi-project collaboration agreements with pharmaceutical companies. These partnerships typically involve upfront payments, research funding, milestone payments tied to discovery and development achievements, and potential downstream royalties on successful programs. The company operates as a drug discovery engine, developing validated targets that are out-licensed to pharma partners for further development and commercialization.
- Spin-out Company Equity: PhoreMost has created spin-out companies from its discovery programs (such as NeoPhore), retaining equity stakes in these ventures. This provides potential upside through equity value appreciation and future liquidity events as spinouts advance through development or attract additional investment.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
PhoreMost product offering
Product offeringCore offering
PhoreMost is a Cambridge UK-based biotechnology company that develops proprietary drug discovery platforms (SITESEEKER and GlueSEEKER) built on its PROTEINi protein interference technology to systematically identify cryptic druggable sites on historically "undruggable" protein targets. The company licenses these platforms to pharmaceutical and biotechnology partners through multi-project collaboration agreements and advances its own internal pipeline of small-molecule and bifunctional degrader oncology programs (PMC-001, PMC-002, PMC-003).
Product overview
PhoreMost is a Cambridge UK-based biotechnology company that has developed a unified platform-plus-pipeline business model centred on its SITESEEKER phenotypic screening technology. SITESEEKER, built on the proprietary PROTEINi (protein interference) technology, probes the entire proteome in live cell environments to systematically unmask cryptic druggable sites. The company leverages this platform both for internal drug discovery programmes (PMC-001, PMC-002, PMC-003) and for partnered collaborations with pharmaceutical companies. The GlueSEEKER platform extends capabilities into molecular glue degrader discovery. PhoreMost's model combines platform-as-a-service partnerships with milestone payments and royalties from internal assets progressing toward clinical development.
Differentiator
Problem solved
Functional benefit
Brands
- SITESEEKER: Next-generation phenotypic screening platform that exploits the dynamics of a live-cell environment to uncover hidden druggable target sites across the entire human genome using proprietary PROTEINi technology
- GlueSEEKER
- PMC-001
- PMC-002
- PMC-003
Products and services
- SITESEEKER Platform
- GlueSEEKER Platform
- PROTEINi Technology
- PMC-001
- PMC-002
- PMC-003
Quantifiable outcome
- 19+ active pharmaceutical partnerships including Boehringer Ingelheim, Roche, and Arvinas, validating the platform's broad applicability.
Companies that use PhoreMost
Customer profileNamed customers9 records
Segments2 records
Ideal customer profiles2 records
PhoreMost technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
PhoreMost partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered flagship, core and minor.
- Boehringer IngelheimflagshipMulti-project drug discovery collaboration using PhoreMost's SITESEEKER platform to identify novel drug targets for Boehringer Ingelheim's pipeline. This flagship partnership demonstrates the platform's applicability to major pharmaceutical R&D operations and provides PhoreMost with significant upfront and milestone payments.
- RocheflagshipMulti-project drug target discovery collaboration leveraging PhoreMost's platform capabilities to identify novel therapeutic targets for Roche's pharmaceutical pipeline across multiple disease areas.
- Otsuka PharmaceuticalcoreMulti-project collaboration utilizing PhoreMost's drug discovery technology platforms to identify novel drug targets for Otsuka's pharmaceutical development programs.
- ArvinascoreMulti-target collaboration for targeted protein degradation using PhoreMost's GlueSEEKER molecular glue degradation platform. This partnership combines PhoreMost's target identification capabilities with Arvinas's expertise in PROTAC development.
- Oxford BiomedicacoreGene therapy discovery collaboration applying PhoreMost's platform technology to identify novel targets and mechanisms for Oxford Biomedica's gene therapy programs.
- Vernalis (Ligand)coreDrug discovery collaboration focused on identifying novel therapeutic targets using Vernalis's fragment-based drug discovery expertise combined with PhoreMost's SITESEEKER platform.
- PlexxikoncoreCollaboration to identify novel drug targets using PhoreMost's platform capabilities, leveraging Plexxikon's expertise in structural biology and fragment-based drug discovery.
- inStem (CCBT)coreStructural biology alliance for drug target characterization and validation, combining inStem's structural biology infrastructure with PhoreMost's target identification capabilities.
- C4X DiscoveryminorNeurodegeneration collaboration focused on identifying novel drug targets for neurodegenerative diseases using PhoreMost's platform technology.
- POLARISqbminorMulti-target collaboration with POLARISqb, combining computational drug design capabilities with PhoreMost's target identification platform.
- Sentinel OncologycoreCollaboration for glioma therapeutic development, applying PhoreMost's SITESEEKER platform to identify novel targets for this aggressive brain cancer indication.
- NeoPhorecoreNeoPhore is a spin-out company created by PhoreMost to advance novel immuno-oncology therapeutics discovered through the SITESEEKER platform, representing the company's approach to creating value through company formation.
- University of CambridgecoreCollaboration on neurodegenerative disease research, combining PhoreMost's platform with academic expertise from the University of Cambridge's world-leading neuroscience research programs.
- Babraham InstitutecoreInnovate UK funding collaboration for research programs conducted at the Babraham Research Campus, where PhoreMost has conducted collaborative research in partnership with the institute.
- o2h discoveryminorDrug discovery collaboration with o2h discovery, combining their medicinal chemistry capabilities with PhoreMost's target identification platform for integrated drug discovery programs.
- The Wistar InstitutecoreAlliance for novel targets in cancer, aging and immune system, combining The Wistar Institute's renowned cancer research expertise with PhoreMost's platform capabilities for target discovery.
- NeoCuraminorResearch collaboration with NeoCura, an emerging biotech company focused on novel cancer therapeutics, applying PhoreMost's platform to identify new targets and mechanisms.
Scale indicators3 records
Recent moves8 records
Expansion highlights6 records
PhoreMost competitors and assessment
Company assessmentDirect peers
- Repare Therapeutics: Repare uses proprietary genomics and phenotypic screening to identify novel precision oncology targets, a screening-by-platform business model that closely parallels PhoreMost's SITESEEKER approach to discovering previously inaccessible cancer targets.
- Foghorn Therapeutics: Foghorn leverages a chromatin biology platform to find druggable sites on chromatin regulatory complexes historically considered undruggable, mirroring PhoreMost's core thesis of unmasking cryptic targets via proprietary screening chemistry.
- Neomorph: Neomorph was a clinical-stage molecular glue degrader biotech with a proprietary ligase discovery platform before its $1.7B acquisition by AbbVie in 2025 — a near-direct comp for PhoreMost's GlueSEEKER, demonstrating the M&A premium for differentiated TPD platforms.
- Kymera Therapeutics: Kymera is a clinical-stage TPD company building a pipeline of heterobifunctional and molecular glue degraders using novel ligases — directly analogous to PhoreMost's GlueSEEKER platform strategy and PMC-003's FBXO22-driven degrader concept.
- Arvinas: Arvinas is a clinical-stage targeted protein degradation company pioneering PROTAC and molecular glue degraders, directly overlapping PhoreMost's GlueSEEKER and FBXO22-based degrader work; it is both an active collaboration partner (multi-target 2022 deal) and a direct competitor in TPD modality discovery.
- Monte Rosa Therapeutics: Monte Rosa is a Boston-based biotech developing molecular glue degraders leveraging proprietary E3 ligase biology, comparably focused on uncovering undruggable protein targets through novel ligase chemistry. Highly comparable to PhoreMost's GlueSEEKER platform and degrader pipeline stance.
Broad incumbents
- Schrödinger: Schrödinger is a larger computational drug discovery platform company partnering with pharma across therapeutic areas; though it focuses on physics-based computation rather than wet-lab phenotypic screening, it serves the same platform-collaboration business archetype as PhoreMost's SITESEEKER offering.
- Exscientia: Exscientia is a UK-based AI-driven drug discovery company with multiple Big Pharma collaborations; it is a broader, more mature version of PhoreMost's platform-plus-partnership model and shares Cambridge UK presence.
Regional players
- C4X Discovery: C4X Discovery is a Manchester UK-based structure-based and phenotypic drug discovery company partnered with PhoreMost on neurodegeneration targets; similar UK SME scale and overlapping target-discovery approach make it a UK peer in the same niche.
Others
- NeoPhore: NeoPhore was spun out of PhoreMost in 2017 with Sixth Element Capital backing to develop small-molecule immuno-oncology therapies built on PhoreMost's SITESEEKER platform; it is economically linked to PhoreMost and serves as a use-case reference for the platform's value-creation pathway.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
PhoreMost social profiles
Digital presencePhoreMost financial estimates
Financial estimateRevenue estimate
Valuation estimate
PhoreMost leadership team
Management profileNumber of profiles
Profiles13 records
PhoreMost subsidiaries and ownership
Company hierarchySubsidiaries1 record
PhoreMost funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PhoreMost M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PhoreMost
What does PhoreMost do?
PhoreMost is a Cambridge UK-based biotechnology company that develops proprietary drug discovery platforms (SITESEEKER and GlueSEEKER) built on its PROTEINi protein interference technology to systematically identify cryptic druggable sites on historically "undruggable" protein targets. The company licenses these platforms to pharmaceutical and biotechnology partners through multi-project collaboration agreements and advances its own internal pipeline of small-molecule and bifunctional degrader oncology programs (PMC-001, PMC-002, PMC-003).
Is PhoreMost a public or private company?
PhoreMost is a private company. It is classified as venture growth investor backed and is currently operating.
When was PhoreMost founded?
PhoreMost was founded in 2015. It employs 1 to 10 people.
Where is PhoreMost based?
PhoreMost is headquartered in Cambridge, United Kingdom, in the Europe region.
How does PhoreMost make money?
Two revenue lines are on record. Pharmaceutical Collaboration Agreements are the primary driver. The others are spin-out Company Equity.
Who are PhoreMost's main competitors?
Direct peers on record are Repare Therapeutics, Foghorn Therapeutics, Neomorph, Kymera Therapeutics, Arvinas and Monte Rosa Therapeutics. Broad incumbents are Schrödinger and Exscientia. C4X Discovery is listed as a regional player. NeoPhore is listed as an others.
Does PhoreMost have an API?
No public API is recorded for PhoreMost.
What industry is PhoreMost in?
PhoreMost's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.